Gabapentin Capsule
Product Images NDC 70518-4740

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (02ae9973 70b1 4bcb A7aa E48351906e74 01)

An illustration showing the formula for calculating creatinine clearance (CLCr), including variables for age, weight, serum creatinine, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Figure1 (02ae9973 70b1 4bcb A7aa E48351906e74 02)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an aminomethyl group and an acetic acid moiety.*

FDA Label Image

Image 1 (02ae9973 70b1 4bcb A7aa E48351906e74 03)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score from 0 to 10. The graph shows the gabapentin line decreasing steadily over time, while the placebo line remains relatively stable.*

FDA Label Image

Image 2 (02ae9973 70b1 4bcb A7aa E48351906e74 04)

A line graph depicting mean pain score over a 7-week period in a study comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks, including a 3-week dose titration period and a subsequent 4-week fixed dose period. The y-axis shows mean pain scores declining from baseline across the study groups.*

FDA Label Image

Image 3 (02ae9973 70b1 4bcb A7aa E48351906e74 05)

A bar graph depicting the proportion of responders, defined as patients with a 50% reduction in pain score, in two separate PHN studies. The graph compares placebo (PBO) and different doses of Gabapentin (GBP 3600 in Study 1, GBP 1800 and GBP 2400 in Study 2), showing response rates in percentage on the vertical axis.*

FDA Label Image

Image 4 (02ae9973 70b1 4bcb A7aa E48351906e74 06)

A scatter plot chart showing the difference percentage versus daily dose in mg from three studies labeled 'study a', 'study b', and 'study c'. Data points indicate the difference (%) at daily doses of approximately 600, 900, 1200, and 1800 mg with distinct markers for each study.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 400 mg capsules packaging label showing a quantity of 30 capsules. The capsule is described as orange/brown. The label includes the NDC number 70518-4740-00 and states the product is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and cautions to keep out of reach of children are also noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.